WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?

+0.41%

+0.12%

-3.32%

-0.93%

-0.70%

Axsome Therapeutics, Inc. AXSM	126.79	+0.41%
CRISPR Therapeutics AG CRSP	41.22	+0.12%
GDS Holdings Ltd. Sponsored ADR Class A GDS	27.67	-3.32%
Insperity, Inc. NSP	86.60	-0.93%
NVIDIA Corporation NVDA	117.70	-0.70%

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?

WeRide Inc. (NASDAQ:WRD) shares rocketed 97.62% after NVIDIA Corporation (NASDAQ:NVDA) disclosed a stake of 1.74 million shares in a 13F filing.
GDS Holdings Limited (NASDAQ:GDS) stock escalated 43.45%, probably after President Trump had reportedly postponed tariffs on packages under $800 from China. Additionally, optimism towards China’s DeepSeek AI model has also lifted stocks recently.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares jumped 42.58% after announcing Merck KGaA (OTC:MKGAF) (OTC:MKKGY) is in advanced discussions to acquire the company.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares increased 40.59%.
Sable Offshore Corp. (NYSE:SOC) stock upped 39.09%.
GeneDx Holdings Corp. (NASDAQ:WGS) shares rose 28.23% after the company announced UltraRapid Whole Genome Sequencing, which will deliver actionable results within 48 hours.
VNET Group, Inc. (NASDAQ:VNET) stock upped 28.22%, probably amid a possible rebound after falling last week due to AI competition concerns related to China’s DeepSeek AI model.
Insperity, Inc. (NYSE:NSP) stock increased 25.99% after the company reported better-than-expected fourth-quarter results.
CRISPR Therapeutics AG (NASDAQ:CRSP) stock grew 25.21% after the company reported better-than-expected fourth-quarter financial results. Several analysts raised the price forecast on the stock.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) stock grew 24.01% after the company reached a settlement agreement with Teva Pharmaceutical (NYSE:TEVA), resolving all patent litigation related to its Auvelity product. Several analysts raised the price forecast on the stock.

Photo via WeRide

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.